Skyhawk Therapeutics anuncia los resultados del ensayo clínico SKY-0515 en la enfermedad de Huntington

Phase 2positiveSKY-0515Positive

AI Analysis

Summary

Skyhawk Therapeutics announced positive 12-month interim results from its Phase 1/2 trial of SKY-0515 in Huntington's disease, demonstrating improvement in Unified Huntington's Disease Rating Scale Composite scores.

Clinical Trial Data

Phase

1/2

Primary Endpoint

Met

Outcome Details

12-month results showed improvement in Unified Huntington's Disease Rating Scale Composite scores

Importance:6/10

Sentiment:

0.70

Huntington's diseasePhase 1/2 trialClinical dataNeurology

Read the original article

Published by PR Newswire Pharma on June 2, 2026 4:50 PM

Read Original